Johnson & Johnson (JNJ)

Cost of Revenue

$30.98B

TTM · Period ending: · USD

JNJ logo

JNJ Cost of Revenue

Latest reported$30.98B
JNJ TTM Cost of Revenue ($0.00 → $30.98B)
High-resolution chart · PNG

JNJ cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Johnson & Johnson Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
30,982,000,000
31,428,000,000
31,005,000,000
30,256,000,000
29,416,000,000
29,076,000,000
28,317,000,000
27,471,000,000
27,141,000,000
26,784,000,000
26,377,000,000
26,553,000,000
27,520,000,000
27,086,000,000
28,543,000,000
29,454,000,000
29,644,000,000
30,722,000,000
30,390,000,000
29,855,000,000
29,714,000,000
29,436,000,000
28,428,000,000
28,427,000,000
27,747,000,000
27,642,000,000
28,003,000,000
27,556,000,000
27,383,000,000
27,105,000,000
27,092,000,000
27,091,000,000
27,373,000,000
27,709,000,000
26,628,000,000
25,423,000,000
23,714,000,000
22,275,000,000
21,765,000,000
21,685,000,000
21,824,000,000
21,562,000,000
21,583,000,000
21,536,000,000
21,716,000,000
21,891,000,000
22,573,000,000
22,746,000,000
22,848,000,000
22,793,000,000
22,243,000,000
22,342,000,000
22,390,000,000
22,643,000,000
22,297,000,000
21,658,000,000
20,993,000,000
20,468,000,000
20,497,000,000
20,360,000,000
20,062,000,000
19,584,000,000
19,042,000,000
18,792,000,000
19,064,000,000
18,904,000,000
18,724,000,000
18,447,000,000
17,507,000,000
17,847,000,000
18,148,000,000
18,511,000,000
18,873,000,000
18,373,000,000
17,980,000,000
17,751,000,000
17,024,000,000
16,400,000,000
15,830,000,000
15,057,000,000
14,674,000,000
14,378,000,000
14,112,000,000
13,996,000,000
14,078,000,000
13,911,000,000
13,551,000,000
13,422,000,000
13,224,000,000
13,017,000,000
12,821,000,000
12,176,000,000
11,465,000,000
11,096,000,000
10,712,000,000
10,447,000,000
10,139,000,000
9,924,000,000
9,714,000,000
9,568,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.